435 related articles for article (PubMed ID: 31533850)
21. Evaluation of prices, availability and affordability of essential medicines in Lahore Division, Pakistan: A cross-sectional survey using WHO/HAI methodology.
Saeed A; Saeed H; Saleem Z; Fang Y; Babar ZU
PLoS One; 2019; 14(4):e0216122. PubMed ID: 31022276
[TBL] [Abstract][Full Text] [Related]
22. Implications of bilateral free trade agreements on access to medicines.
Correa CM
Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
[TBL] [Abstract][Full Text] [Related]
23. Poverty, health & intellectual property rights with special reference to India.
Satyanarayana K; Srivastava S
Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
[TBL] [Abstract][Full Text] [Related]
24. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
Velasquez G
Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
[TBL] [Abstract][Full Text] [Related]
25. Trade agreements, intellectual property, and the role of the World Bank in improving access to medicines in developing countries.
Rovira J
Yale J Health Policy Law Ethics; 2004; 4(2):401-13. PubMed ID: 15536921
[No Abstract] [Full Text] [Related]
26. Basic survival needs and access to medicines--coming to grips with TRIPS: conversion + calculation.
Van Puymbroeck RV
J Law Med Ethics; 2010; 38(3):520-49. PubMed ID: 20880239
[TBL] [Abstract][Full Text] [Related]
27. Medicine procurement and the use of flexibilities in the Agreement on Trade-Related Aspects of Intellectual Property Rights, 2001-2016.
't Hoen EF; Veraldi J; Toebes B; Hogerzeil HV
Bull World Health Organ; 2018 Mar; 96(3):185-193. PubMed ID: 29531417
[TBL] [Abstract][Full Text] [Related]
28. Country and regional variations in purchase prices for essential cancer medications.
Cuomo RE; Seidman RL; Mackey TK
BMC Cancer; 2017 Aug; 17(1):566. PubMed ID: 28836947
[TBL] [Abstract][Full Text] [Related]
29. Access and use of WHO essential medicines in Italy.
Petrella A; Fortinguerra F; Cangini A; Pierantozzi A; Trotta F
Front Public Health; 2023; 11():1211208. PubMed ID: 37881343
[TBL] [Abstract][Full Text] [Related]
30. Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain.
Roitberg F; Amaral T; Cherny NI; Giuliani R; Latino NJ; Galotti M; Bricalli G; Curigliano G; Pentheroudakis G; Trapani D
ESMO Open; 2023 Oct; 8(5):101617. PubMed ID: 37672862
[TBL] [Abstract][Full Text] [Related]
31. Modernizing the World Health Organization List of Essential Medicines for Preventing and Controlling Cardiovascular Diseases.
Kishore SP; Blank E; Heller DJ; Patel A; Peters A; Price M; Vidula M; Fuster V; Onuma O; Huffman MD; Vedanthan R
J Am Coll Cardiol; 2018 Feb; 71(5):564-574. PubMed ID: 29406862
[TBL] [Abstract][Full Text] [Related]
32. Policy space for health and trade and investment agreements.
Koivusalo M
Health Promot Int; 2014 Jun; 29 Suppl 1():i29-47. PubMed ID: 25217355
[TBL] [Abstract][Full Text] [Related]
33. Affordable antiretroviral drugs for the under-served markets: how to expand equitable access against the backdrop of challenging scenarios?
Dionisio D; Cao Y; Hongzhou L; Kraisintu K; Messeri D
Curr HIV Res; 2006 Jan; 4(1):3-20. PubMed ID: 16454707
[TBL] [Abstract][Full Text] [Related]
34. The role of intellectual property rights on access to medicines in the WHO African region: 25 years after the TRIPS agreement.
Motari M; Nikiema JB; Kasilo OMJ; Kniazkov S; Loua A; Sougou A; Tumusiime P
BMC Public Health; 2021 Mar; 21(1):490. PubMed ID: 33706726
[TBL] [Abstract][Full Text] [Related]
35. ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe.
Cherny NI; Sullivan R; Torode J; Saar M; Eniu A
Ann Oncol; 2017 Nov; 28(11):2633-2647. PubMed ID: 28950323
[TBL] [Abstract][Full Text] [Related]
36. The morally uncomfortable global drug gap.
Cohen-Kohler JC
Clin Pharmacol Ther; 2007 Nov; 82(5):610-4. PubMed ID: 17898710
[TBL] [Abstract][Full Text] [Related]
37. The essential drugs concept is needed now more than ever.
Smith MK; Tickell S
Trans R Soc Trop Med Hyg; 2003; 97(1):2-5. PubMed ID: 12886792
[TBL] [Abstract][Full Text] [Related]
38. Use of evidence and negotiation in the review of national standard treatment guidelines and essential medicines list: experience from Ghana.
Koduah A; Asare BA; Gavor E; Gyansa-Lutterodt M; Andrews Annan E; Ofei FW
Health Policy Plan; 2019 Nov; 34(Supplement_2):ii104-ii120. PubMed ID: 31723963
[TBL] [Abstract][Full Text] [Related]
39. The interpretation of China national essential medicines list 2018.
Zuo W; Mei D; Sun W; Tang X; Niu Z; Gao D; Zhang B
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):191-200. PubMed ID: 31914825
[No Abstract] [Full Text] [Related]
40. Rare essentials: drugs for rare diseases as essential medicines.
Stolk P; Willemen MJ; Leufkens HG
Bull World Health Organ; 2006 Sep; 84(9):745-51. PubMed ID: 17128345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
